Health Condition 1: F30-F39- Mood [affective] disorders
Conditions
Interventions
Intervention1: Co-enzymeQ10 400 mg once a day for 30 days: Co-enzymeQ10 400 mg once a day for 30 days with standard anti-depressant therapy
Control Intervention1: Placebo: Placebo capsules with standa
Sponsors
AIIMS
Eligibility
Inclusion criteria
Inclusion criteria: 1. All adult patients of either sex aged 18-65 years with clinical diagnosis of Major Depressive Disorder as per DSM-5 criteria. 2. Patients on stable dose (no change in dose) of anti-depressants for 4 weeks. 3. Patients willing to participate and give consent.
Exclusion criteria
Exclusion criteria: 1. Patients with comorbid psychiatric or neurological disorders such as anxiety disorder, schizophrenia, current state of psychosis, epilepsy and substance use disorder 2. Patient currently having suicidal ideas or history of suicidal plan/attempt. ï?§ Pregnancy or lactation or expecting to get pregnant during the treatment. ï?§ Patient on concomitant warfarin therapy, anti-hypertensive drugs or statins. ï?§ Patients with chronic liver disease. ï?§ Poor adherence to medications. ï?§ Patient not willing to give consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ï?§ To evaluate the effect of add on COQ10 on depressive symptoms as assessed by MADRS in patients with Major depressive disorder after 4 weeks of therapy.Timepoint: ï?§ To evaluate the effect of add on COQ10 on depressive symptoms as assessed by MADRS in patients with Major depressive disorder after 4 weeks of therapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To evaluate the change in serum IDO and serum BDNF after 4 weeks of add on CoQ10 therapy. 2. To evaluate the change in cognition score after 4 weeks of add-on CoQ10 therapy. 3. To evaluate the safety of add on COQ10. Timepoint: At baseline and 4 weeks | — |
Countries
India
Contacts
Public ContactBhupinder Solanki
AIIMS
Outcome results
None listed